The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world treatment characteristics for first-line therapy (1L) of advanced hepatocellular carcinoma (HCC) in Canada and Europe.
 
Sharlene Gill
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Lilly; Shire; Taiho Pharmaceutical
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Celgene
 
Dena H Jaffe
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ironwood Pharmaceuticals (Inst); Janssen (Inst); Lilly (Inst); Pfizer (Inst)
 
Marc DeCongelio
Stock and Other Ownership Interests - Celgene
Consulting or Advisory Role - Abbvie (Inst); Alnylam (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Sanofi (Inst); Seagen (Inst); Valeant Pharmaceuticals International (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
 
Arnold N. DuBell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
 
Jing Shi
Employment - Abbott (I)
 
Tami Wisniewski
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Gwilym Thompson
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb